Research view
Switch to patient viewEndometrial cancer: trials that stopped early
Trials on Endometrial cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
57 stopped trials give a reason in the registry, latest registry update first.
Terminated
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
Reason given in the registry “Low accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Aug 2025.
- Ended
- May 2025
- Phase
- Phase 2/3
- Run by
- University Health Network, Toronto
- Registry record
- NCT04159155
Terminated
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Reason given in the registry “Business decision”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2025.
- Ended
- Apr 2025
- Phase
- Phase 1
- Run by
- Numab Therapeutics AG
- Registry record
- NCT06299163
Terminated
Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer
Reason given in the registry “Patients were recruited during screen phase but fewer patients met criteria.”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Jul 2025.
- Ended
- Jun 2025
- Phase
- Phase 2
- Run by
- National Cheng-Kung University Hospital
- Registry record
- NCT04030429
Terminated
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Reason given in the registry “At the time of study termination, both fruquintinib and tislelizumab are commercially available in the United States.”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2025.
- Ended
- Jun 2024
- Phase
- Phase 1/2
- Run by
- Hutchmed
- Registry record
- NCT04577963
Terminated
A Biomarker Screening Protocol for Participants With Solid Tumors
Reason given in the registry “Pipeline Reprioritization”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Jul 2025.
- Ended
- Feb 2025
- Run by
- Lyell Immunopharma, Inc.
- Registry record
- NCT05891197
Terminated
A Study to Investigate LYL797 in Adults With Solid Tumors
Reason given in the registry “Pipeline Reprioritization”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Jul 2025.
- Ended
- Nov 2024
- Phase
- Phase 1
- Run by
- Lyell Immunopharma, Inc.
- Registry record
- NCT05274451
Suspended
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Reason given in the registry “Business decision”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Jun 2025.
- Ended
- Sept 2025
- Phase
- Phase 1
- Run by
- NextPoint Therapeutics, Inc.
- Registry record
- NCT05958199
Terminated
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Reason given in the registry “Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority.”
Quoted unchanged from ClinicalTrials.gov; record updated 28 May 2025.
- Ended
- Dec 2024
- Phase
- Phase 1
- Run by
- Pfizer
- Registry record
- NCT04152018
Terminated
Bariatric Education for Women With Obesity and Endometrial Cancer
Reason given in the registry “No Surgeon to perform the operations.”
Quoted unchanged from ClinicalTrials.gov; record updated 15 May 2025.
- Ended
- Apr 2025
- Run by
- University of Oklahoma
- Registry record
- NCT05396794
Withdrawn
Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer
Reason given in the registry “IMP owner decision”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Apr 2025.
- Ended
- Apr 2026
- Phase
- Phase 1/2
- Run by
- Vall d'Hebron Institute of Oncology
- Registry record
- NCT06385548
Terminated
A Study of SGN-ALPV in Advanced Solid Tumors
Reason given in the registry “Study closed due to portfolio prioritization”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Feb 2025.
- Ended
- Dec 2023
- Phase
- Phase 1
- Run by
- Seagen Inc.
- Registry record
- NCT05229900
Terminated
A Study of SGN-STNV in Advanced Solid Tumors
Reason given in the registry “Study closed due to portfolio prioritization”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Feb 2025.
- Ended
- Mar 2024
- Phase
- Phase 1
- Run by
- Seagen Inc.
- Registry record
- NCT04665921
Withdrawn
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Reason given in the registry “A business decision was made to not initiate this study.”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Jan 2025.
- Phase
- Phase 1
- Run by
- Astellas Pharma Global Development, Inc.
- Registry record
- NCT06681870
Terminated
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Reason given in the registry “Required re-formulation of DFMO from IV to capsule to maintain safety”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Dec 2024.
- Ended
- Dec 2024
- Phase
- Phase 1/2
- Run by
- Aminex Therapeutics, Inc.
- Registry record
- NCT05500508
Withdrawn
Niraparib in High-grade Endometrial Cancer Trial
Reason given in the registry “Unable to obtain funding”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Dec 2024.
- Ended
- Jan 2026
- Phase
- Early phase 1
- Run by
- Sir Mortimer B. Davis - Jewish General Hospital
- Registry record
- NCT05289648
Withdrawn
Laser Treatment of Genito-urinary Syndrome in Women
Reason given in the registry “Hospital terminated treatment with laser”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2024.
- Run by
- Herning Hospital
- Registry record
- NCT03238053
Withdrawn
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
Reason given in the registry “Lack of accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.
- Ended
- Aug 2024
- Phase
- Phase 1
- Run by
- Brown University
- Registry record
- NCT05655598
Terminated
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Reason given in the registry “Lack of Funding - no safety issue with Drug; Company Permanently Closed”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Aug 2024.
- Ended
- Jun 2024
- Phase
- Phase 1/2
- Run by
- Elucida Oncology
- Registry record
- NCT05001282
Terminated
Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer
Reason given in the registry “This was a national survey of physicians. Per the protocol, they were only allowed to be contacted twice and they received less surveys back than anticipated.”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Apr 2024.
- Ended
- Feb 2024
- Run by
- Wake Forest University Health Sciences
- Registry record
- NCT05877404
Withdrawn
PET/MRI in Endometrial Cancer
Reason given in the registry “Unable to enroll patients to study”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Apr 2024.
- Ended
- Feb 2026
- Run by
- Massachusetts General Hospital
- Registry record
- NCT05390021
Withdrawn
Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer
Reason given in the registry “The study is being closed based on corporate changes at EQRx and is not related to any efficacy or safety issues with lerociclib.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Nov 2023.
- Ended
- Mar 2025
- Phase
- Phase 3
- Run by
- EQRx International, Inc.
- Registry record
- NCT05712941
Withdrawn
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
Reason given in the registry “Slow Accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Feb 2023.
- Phase
- Phase 2
- Run by
- Haider Mahdi
- Registry record
- NCT05419817
Suspended
Guangzhou Women's Health Cohort Study (GWHCS)
Reason given in the registry “Due to the rebound of the COVID-19 epidemic in the city, we have to suspend the project temporarily.”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Feb 2023.
- Ended
- Aug 2026
- Run by
- Guangzhou Women and Children's Medical Center
- Registry record
- NCT05506800
Suspended
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
Reason given in the registry “Company decision”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Dec 2022.
- Ended
- Jan 2024
- Phase
- Phase 1/2
- Run by
- Clovis Oncology, Inc.
- Registry record
- NCT04042116
Withdrawn
Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers
Reason given in the registry “Salarius discontinued support”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Mar 2022.
- Ended
- Jun 2024
- Phase
- Phase 1
- Run by
- HonorHealth Research Institute
- Registry record
- NCT04611139
Suspended
Effect of a Lifestyle Intervention on Nutritional Status and Prognosis of Endometrial Cancer Survivors
Reason given in the registry “Study stopped due to COVID-19 pandemic, as conducting a behaviour-change programme in groups was not recommended to prevent the spread of the virus.”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Jul 2021.
- Ended
- Nov 2025
- Run by
- Brazilian National Cancer Institute
- Registry record
- NCT03095664
Withdrawn
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
Reason given in the registry “PI is leaving institution”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Nov 2020.
- Phase
- Phase 2
- Run by
- Case Comprehensive Cancer Center
- Registry record
- NCT04197219
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.